Table 3. List of SNPs Associated with Clozapine/Olanzapine (RiskMed) Induced Weight Gain at Genotypic and/or Allelic Level.
| SNP (location, bp) | Geno- type | Weight change (%)a All patients | p-value | Weight change (%)a All patients RiskMed | p-value | Weight change (%)a European Americans RiskMed | p-valueb | Allele | Count (freq) | Weight change (%) (variance) European Americans RiskMed | p-value | HWE p-value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| rs806378 (88916270) | CC | 5.20±7.29 (102) | 0.873 | 5.82±7.44 (78) | 0.763 | 2.69±5.45 (39) | 0.025 | C | 117 (0.69) | 3.84 (31.4) | 0.035 | 0.619 |
| CT | 5.20±7.30 (66) | 6.34±6.18 (46) | 6.14±5.68 (39) | T | 53 (0.31) | 5.83 (31.4) | ||||||
| TT | 4.36±4.59 (12) | 4.48±4.78 (8) | 4.95±4.96 (7) | |||||||||
| rs806380 (88921372) | GG | 4.69±4.06 (16) | 0.947 | 4.69±4.11 (11) | 0.871 | 5.04±4.15 (10) | 0.071 | G | 66 (0.39) | 5.35 (32.1) | 0.078 | 0.257 |
| GA | 4.93±5.94 (78) | 5.65±6.17 (55) | 5.49±5.89 (46) | A | 104 (0.61) | 3.77 (32.1) | ||||||
| AA | 5.19±7.52 (81) | 5.85±7.50 (63) | 2.41±5.63 (29) | |||||||||
| rs2180619 (88934671) | GG | 4.85±6.31 (39) | 0.876 | 5.72±6.97 (29) | 0.694 | 2.53±5.58 (12) | 0.295 | G | 68 (0.4) | 3.54 (31.9) | 0.097 | 0.651 |
| GA | 5.07±6.43 (86) | 5.17±6.89 (61) | 4.17±5.54 (43) | A | 102 (0.6) | 5.00 (31.9) | ||||||
| AA | 5.51±6.02 (49) | 6.36±6.24 (38) | 5.50±6.01 (30) | |||||||||
| rs9450902 (88936943) | GG | 7.58±9.69 (5) | 0.674 | 8.06±11.13 (4) | 0.753 | −3.41 (1) | 0.071 | G | 14 (0.08) | 1.21 (31.5) | 0.019 | 0.441 |
| GC | 4.96±6.60 (39) | 5.38±7.03 (30) | 2.15±3.93 (11) | C | 156 (0.92) | 4.75 (31.5) | ||||||
| CC | 4.93±6.41 (132) | 5.70±6.38 (96) | 4.92±5.86 (73) | |||||||||
| rs10485170 (88939371) | TT | 4.87±6.55 (139) | 0.362 | 5.50±6.55 (101) | 0.457 | 4.78±5.79 (76) | 0.087 | T | 162 (0.93) | 4.62 (31.2) | 0.034 | 0.334 |
| TC | 6.57±7.14 (37) | 7.37±7.89 (27) | 2.15±4.15 (10) | C | 12 (0.07) | 1.22 (31.2) | ||||||
| CC | 6.23±8.44 (4) | 6.23±8.44 (4) | −3.41 (1) |
a
Mean±SD (number of individuals).
b
SNPs with only one individual in a genotypic group were merged with the heterozygous genotypic group. All the p-values were calculated using ANOVA. rs806378: CC vs TT+TC, 2.69±5.46 vs 5.97±5.54, p=0.008; Bonferroni corrected p=0.153; FDR q-value=0.12; rs806380: AA vs GG+GA, 2.41±5.62 vs 5.41±5.59, p=0.022; Bonferroni corrected p=0.432, FDR q-value=0.165; HWE: Hardy–Weinberg equilibrium, calculated for the patients with European ancestry on RiskMed (clozapine and olanzapine); values in bold indicate significance.